Spravato is the first esketamine nasal spray medication, taken with an oral antidepressant, that treats depressive symptoms in adults with major depressive disorder with suicidal thoughts or actions.
Spravato targets the N-methyl-D-aspartate (NMDA) receptor and is believed to work differently than currently available oral antidepressants. This FDA-approved treatment has been safety evaluated in over 1700 adults with treatment-resistant depression (TRD) across six studies: Five Phase 3 studies and one Phase 2 dose ranging study.
Because of the risks for sedation, dissociation, and abuse and misuse, Spravato is only available at healthcare settings certified in the Spravato Risk Evaluation and Mitigation Strategy (REMS) Program, under the supervision of a healthcare provider.
You'll take Spravato twice a week for four weeks, along with an oral antidepressant. You should not stop taking Spravato without talking to your healthcare provider.
After four weeks, you and your healthcare provider will evaluate and determine the need for continued treatment. Dosing frequency will be individualized to the lowest frequency required to maintain remission/response.